Screening for prostate cancer is neither appropriate nor cost-effective

Urologic Clinics of North America

Volumn 23, Issue 4, 1996, Pages 521-530

  Albertsen, P C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0030480403     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70332-3     Document Type: Article

References (58)

1. F. Adair J. Berg L. Joubert Long-term follow-up of breast cancer patients: The 30 year report Cancer 33 1974 1145 1150
2. H.O. Adami J.A. Baron K.J. Rothman Ethics of a prostate cancer screening trial Lancet 343 1994 958 960
3. M. Aihara T.M. Wheeler M. Ohori Heterogeneity of prostate cancer in radical prostatectomy specimens Urology 43 1994 60 66
4. P.C. Albertsen D.G. Fryback B.E. Storer Long-term survival among men with conservatively treated, localized prostate cancer JAMA 274 1995 626 631
5. G.L. Andriole W.J. Catalona Using PSA to screen for prostate cancer Urol Clin North Am 20 1993 647 651
6. M.J. Barry C. Fleming C.M. Coley Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate Urology 46 1995 2 13
7. M.J. Barry C. Fleming C.M. Coley Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes Urology 46 1995 277 289
8. M.J. Barry C. Fleming C.M. Coley Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program Urology 46 1995 445 461
9. J.R. Beck M.W. Kattan B.J. Miles A critique of the decision analysis for clinically localized prostate cancer J Urol 152 1994 1894 1899
10. R.M. Benoit M.J. Naslund An economic rationale for prostate cancer screening Urology 44 1994 795 803
11. C.C. Boring T.S. Squires T. Tong Cancer statistics, 1994 CA Cancer J Clin 44 1994 7 26
12. H.B. Carter J.D. Pearson J. Mettler Longitudinal evaluation of prostate-specific antigen in levels in men with and without prostate disease JAMA 267 1992 2215 2220
13. W.J. Catalona Screening for prostate cancer: Enthusiasm [editorial] Urology 42 1993 113 115
14. W.J. Catalona J.P. Ritchie F.R. Ahmann Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of multicenter clinical trial of 6630 men J Urol 151 1994 1283 1290
15. W.J. Catalona D.S. Smith T.L. Ratliff Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening JAMA 270 1993 948 954
16. W.J. Catalona D.S. Smith T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
17. W.J. Catalona D.S. Smith R.L. Wolfert Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening JAMA 274 1995 1214 1220
18. G.W. Chodak Questioning the value of screening for prostate cancer in asymptomatic men Urology 42 1993 116 118
19. G.W. Chodak R.A. Thisted G.S. Gerber Results of conservative management of clinically localized prostate cancer N Engl J Med 330 1994 242 248
20. C.M. Coley M.J. Barry C. Fleming Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies Urology 46 1995 125 141
21. L.J. Denis To screen or not to screen? Prostate Suppl 4 1992 63 70
22. V.J. Dorr S.K. Williamson R.L. Stephens An evaluation of prostate-specific antigen as a screening test for prostate cancer Arch Intern Med 153 1993 2529 2537
23. D.M. Eddy Clinical decision making: From theory to practice; three battles to watch in the 1990's JAMA 270 1993 520 526
24. D.M. Eddy Clinical decision making: Principles for making difficult decisions in difficult times JAMA 271 1994 1792 1798
25. J.I. Epstein P.C. Walsh M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
26. C. Fleming J.H. Wasson P.C. Albertsen A decision analysis of alternative treatment strategies for clinically localized prostate cancer JAMA 269 1993 2650 2658
27. R.S. Fontana Screening for lung cancer: Recent experience in the United States Hansen H.H. Lung Cancer: Basic and Clinical Aspects 1986 Kluwer Boston
28. J. Frisell G. Eklund L. Hellstrom Analysis of interval breast carcinomas in a randomized screening trial in Stockholm Breast Cancer Res Treat 9 1987 219 225
29. P.H. Gann C.H. Hennekens M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
30. G.S. Gerber G.W. Chodak Routine screening for cancer of the prostate J Natl Cancer Inst 83 1991 329 335
31. G.S. Gerber I.M. Thompson R. Thisted Disease-specific survival following routine prostate cancer screening by digital rectal examination JAMA 269 1993 61 64
32. J.K. Gohagan B.S. Kramer P. Greenwald Screening for prostate cancer Am J Prev Med 10 1994 245 246
33. W. Halsted The results of operations for cure of cancer of the breast performed at the Johns Hopkins Hospital Johns Hopkins Hosp Bull 4 1894 497 555
34. J.A. Hanley G. McGregor Screening for cancer of the prostate: An evaluation of benefits, unwanted health effects and costs. Conseil d'e´valuation des technologies de la sante´ due Que´bec 1995 CETS Montreal
35. B.E. Hillner D.G. McLeod E.D. Crawford Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer Urology 45 1995 633 640
36. Hinman F. Jr Screening for prostatic carcinoma J Urol 145 1991 126 130
37. B.S. Hulka Cancer screening. Degrees of proof and practical application Cancer 62 1988 1776 1780
38. S.J. Jacobsen S.K. Katusic E.J. Bergstralh Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing JAMA 274 1995 1445 1449
39. M.D. Krahn J.E. Mahoney M.H. Eckman Screening for prostate cancer: A decision analytic view JAMA 272 1994 773 780
40. B.S. Kramer M.L. Brown P.C. Prorok Prostate cancer screening: What we know and what we need to know Ann Intern Med 119 1993 914 923
41. P.J. Littrup A.C. Goodman C.J. Mettlin The benefit and cost of prostate cancer early detection CA Cancer J Clin 43 1993 134 149
42. G.L. Lu-Yao A.L. Potosky P.C. Albertsen Follow-up prostate cancer treatments after radical prostatectomy—A population based study J Nat Cancer Inst 88 1996 166 173
43. B.A. Miller L.A.G. Ries B.F. Hankey SEER Cancer Statistics Review: 1973–1990. National Cancer Institute 1993 National Institute of Health, NIH Pub No. Washington, DC 93 2778
44. A.S. Morrison Intermediate determinants of mortality in the evaluation of screening Int J Epidemiol 20 1991 642 650
45. D. Neuhauser A.M. Lewicki What do we gain from the sixth stool quaiac? N Engl J Med 293 1975 226 228
46. M. Ohori T.M. Wheeler P.T. Scardino The new American joint committee on cancer and international union against cancer TNM classification of prostate cancer: Clinicopathologic correlations Cancer 74 1994 104 114
47. S.A. Optenburg I.M. Thompson Economics of screening for carcinoma of the prostate Urol Clin North Am 17 1990 719 737
48. S.L. Parker T. Tong B.A. Bolden Cancer Statistics, 1995 CA Cancer J Clin 46 1996 5 28
49. A.L. Potosky B.A. Miller P.C. Albertsen The role of increasing detection in the rising incidence of prostate cancer JAMA 273 1995 548 552
50. J.P. Richie L.F. Ratliff W.J. Catalona Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination Urology 42 1993 365 374
51. D.L. Sackett R.B. Haynes G.H. Guyatt Clinical Epidemiology: A Basic Science for Clinical Medicine 1991 Little Brown Boston
52. P.T. Scardino R. Weaver M.A. Hudson Early detection of prostate cancer Hum Pathol 23 1992 211 222
53. K.M. Slawin M. Ohori O. Dillioglugil P.T. Scardino Screening for prostate cancer: An analysis of early experience CA Cancer J Clin 45 1995 134 147
54. T.A. Stamey F.S. Freiha J.E. McNeal Localized prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 1993 933 938
55. U.H. Stenman J. Leinonen H. Alfthan A complex between prostate-specific antigen and alpha 1-antichymotripsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer Cancer Res 51 1993 222 226
56. US Preventive Services Task Force Screening for prostate cancer: Commentary on the recommendations of the Canadian Task Force on the Periodic Health Examination Am J Prev Med 10 1994 187 193
57. Vital and Health Statistics Causes of death contributing to changes in life expectancy: United States, 1984–1989, Series Data from the National Vital Statistics System, No. 23 20 1994 United States Department of Health and Human Services, Publication No. (PHS) Hyattsville, MD 94 1851
58. P.C. Walsh Prostate cancer kills: Strategy to reduce deaths Urology 44 1994 463 466